Intellia Therapeutics (NTLA) Projected to Post Earnings on Thursday

Intellia Therapeutics (NASDAQ:NTLA) is anticipated to release its earnings data before the market opens on Thursday, February 27th. Analysts expect Intellia Therapeutics to post earnings of ($1.32) per share and revenue of $8.10 million for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Intellia Therapeutics Stock Down 5.4 %

Shares of NASDAQ NTLA opened at $11.51 on Tuesday. The firm has a market capitalization of $1.17 billion, a P/E ratio of -2.12 and a beta of 1.80. The stock’s 50-day simple moving average is $10.99 and its two-hundred day simple moving average is $15.87. Intellia Therapeutics has a twelve month low of $8.96 and a twelve month high of $34.87.

Analyst Ratings Changes

A number of brokerages have weighed in on NTLA. Chardan Capital upped their target price on Intellia Therapeutics from $88.00 to $91.00 and gave the stock a “buy” rating in a research note on Monday, November 18th. The Goldman Sachs Group decreased their target price on Intellia Therapeutics from $19.00 to $12.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 14th. BMO Capital Markets reduced their price objective on Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating on the stock in a research report on Friday, January 10th. Morgan Stanley lowered Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $56.00 to $11.00 in a research report on Monday, January 27th. Finally, Barclays reduced their price objective on Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating on the stock in a research report on Friday, November 8th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Intellia Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $48.71.

Insider Activity at Intellia Therapeutics

In related news, CEO John M. Leonard sold 26,807 shares of the stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $12.18, for a total transaction of $326,509.26. Following the completion of the sale, the chief executive officer now directly owns 941,115 shares in the company, valued at $11,462,780.70. This represents a 2.77 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders sold 29,000 shares of company stock worth $352,551 in the last ninety days. 3.20% of the stock is owned by company insiders.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.